Key facts
- It has raised $160K; the latest was Early Stage VC ($150K) in Oct 2025.
- Notable investors include Virginia Innovation Partnership Corporation, Cville BioHub.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Overa Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Overa Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Overa Therapeutics
Developer of cancer therapeutics designed to target oncology-gamete antigens. The company focuses on the development candidate antibody-drug conjugate for testing in human trials, enabling scientific professionals to find aid in cancer treatment.
- Sector
- Healthcare
- HQ
- Richmond, VA, United States
- Ownership
- Privately Held (backing)
Overa Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Overa Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Overa Therapeutics in its N-PORT filings yet. We sweep new filings monthly.